
1. aids res hum retroviruses. 2012 feb;28(2):156-64. doi: 10.1089/aid.2010.0370.
epub 2011 may 6.

plasma raltegravir exposure influences antiviral activity selection of
resistance mutations.

garrido c(1), de mendoza c, alvarez e, garcía f, morello j, garcia s, ribera e,
rodríguez-novoa s, gutierrez f, soriano v; sinres team.

collaborators: pedreira j, iribarren ja, solá j, téllez mj, estrada v, garcía s, 
arribas jr, santos l, miralles p, losa je, cervero m, sanz j, barros c, górgolas 
m, ribera e, vidal c, riera m, gómez c, chocarro a, galindo mj, gutiérrez f,
viciana i, santos j, omar m, collado a, gálvez c, lozano a, fernández jm,
gutiérrez-ravé v, ruz ma, hidalgo c, pasquau j, garcía f, guillot v,
hernández-quero j, pineda ja, garrido c, anta l, de mendoza c, soriano v.

author information: 
(1)infectious diseases department, hospital carlos iii, madrid, spain.

raltegravir (ral) resistance associated selection integrase
mutations positions 92, 143, 148, and/or 155. substantial proportion ral 
failures, however, occurs absence changes. examination ral 
plasma concentrations may help interpreting observation. early ral
virological failures seen 22 clinics spain 2009 identified. hiv
integrase sequences ral plasma trough concentrations (c(t)) examined. 
total 106 patients experiencing virological failure ral identified.
only earliest sample failure examined. integrase sequences could be
obtained 89 (84%), 30 (33.7%) depicted primary ral resistance
mutations (15 n155h, eight q148h/r, three y143r, one e92q, three than
one them). another nine (10.1%) patients showed secondary changes. the
remaining 50 ral early failures (56.2%) select integrase change. ral 
c(t) could measured 66 patients failure 21 before
failure. control group 37 patients viral suppression ral,
detectable plasma levels seen cases, greater median ral c(t)
than failures, either time viral rebound (p<0.001) it
(p=0.055). moreover, median c(t) time failure greater patients
selecting primary ral resistance mutations rest failures
(p<0.001). undetectable ral c(t) seen patients failing ral without
integrase resistance mutations (64.1% them). ral failures absence of
integrase resistance mutations mainly reflect poor drug compliance.

doi: 10.1089/aid.2010.0370 
pmid: 21457126  [indexed medline]

